Whitehawk Therapeutics (NASDAQ:WHWK) CEO David James Lennon Sells 5,100 Shares

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 5,100 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $3.31, for a total value of $16,881.00. Following the completion of the sale, the chief executive officer directly owned 44,579 shares of the company’s stock, valued at approximately $147,556.49. This represents a 10.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Whitehawk Therapeutics Trading Down 1.2%

NASDAQ WHWK traded down $0.05 during trading on Tuesday, reaching $4.03. 276,413 shares of the company’s stock were exchanged, compared to its average volume of 145,267. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $4.48. The company’s fifty day simple moving average is $2.93 and its 200-day simple moving average is $2.44.

Hedge Funds Weigh In On Whitehawk Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quadrature Capital Ltd bought a new stake in Whitehawk Therapeutics in the fourth quarter worth approximately $28,000. ABG Innovation Capital Partners III GP Ltd bought a new position in Whitehawk Therapeutics during the third quarter valued at about $51,000. Dimensional Fund Advisors LP bought a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $84,000. Squarepoint Ops LLC bought a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at approximately $159,000. Finally, Marshall Wace LLP acquired a new stake in Whitehawk Therapeutics in the 4th quarter worth approximately $164,000. Institutional investors own 52.08% of the company’s stock.

Analysts Set New Price Targets

WHWK has been the topic of a number of research analyst reports. JonesTrading assumed coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective on the stock. Oppenheimer started coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.50.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.